deltatrials
Terminated PHASE1 INTERVENTIONAL 1-arm NCT03420963

Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors

Ex-Vivo Expanded Allogeneic NK Cells for the Treatment of Solid Tumors of Pediatric Origin in Children and Young Adults

Sponsor: M.D. Anderson Cancer Center

Conditions Recurrent Cutaneous Melanoma Recurrent Lip and Oral Cavity Carcinoma Recurrent Malignant Endocrine Neoplasm Recurrent Malignant Female Reproductive System Neoplasm Recurrent Malignant Male Reproductive System Neoplasm Recurrent Malignant Mesothelioma Recurrent Malignant Neoplasm of Multiple Primary Sites Recurrent Malignant Oral Neoplasm Recurrent Malignant Pharyngeal Neoplasm Recurrent Malignant Skin Neoplasm Recurrent Malignant Soft Tissue Neoplasm Recurrent Malignant Solid Neoplasm Recurrent Malignant Thyroid Gland Neoplasm Recurrent Malignant Urinary System Neoplasm Refractory Cutaneous Melanoma Refractory Malignant Bone Neoplasm Refractory Malignant Endocrine Neoplasm Refractory Malignant Female Reproductive System Neoplasm Refractory Malignant Male Reproductive System Neoplasm Refractory Malignant Mesothelioma Refractory Malignant Neoplasm of Multiple Primary Sites Refractory Malignant Oral Neoplasm Refractory Malignant Pharyngeal Neoplasm Refractory Malignant Skin Neoplasm Refractory Malignant Soft Tissue Neoplasm Refractory Malignant Solid Neoplasm Refractory Malignant Thyroid Gland Neoplasm Refractory Malignant Urinary System Neoplasm
Interventions Cord Blood-derived Expanded Allogeneic Natural Killer Cells Cyclophosphamide Etoposide
Updated 22 times since 2018 Last updated: Feb 27, 2026 Started: Aug 31, 2018 Primary completion: Feb 26, 2026 Completion: Feb 26, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

\<75% participation

Other terminated trials from M.D. Anderson Cancer Center

See all terminations from M.D. Anderson Cancer Center

This PHASE1 trial investigates Recurrent Cutaneous Melanoma and Recurrent Lip and Oral Cavity Carcinoma and is currently terminated or withdrawn. M.D. Anderson Cancer Center leads this study, which shows 22 recorded versions since 2018 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Oct 2018 · 2 months · monthly snapshot~Oct 2018 – ~Dec 2018 · 2 months · monthly snapshot~Dec 2018 – ~Jun 2019 · 6 months · monthly snapshot~Jun 2019 – ~Apr 2020 · 10 months · monthly snapshot~Apr 2020 – ~Jun 2020 · 2 months · monthly snapshot~Jun 2020 – ~Sep 2020 · 3 months · monthly snapshot~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshot~Jan 2021 – ~May 2021 · 4 months · monthly snapshot~May 2021 – ~Sep 2022 · 16 months · monthly snapshot~Sep 2022 – ~Oct 2023 · 13 months · monthly snapshot~Oct 2023 – ~Dec 2023 · 2 months · monthly snapshot~Dec 2023 – ~Jun 2024 · 6 months · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Dec 2024 · 3 months · monthly snapshot~Dec 2024 – ~Mar 2025 · 3 months · monthly snapshot~Mar 2025 – ~Sep 2025 · 6 months · monthly snapshot~Sep 2025 – ~Feb 2026 · 5 months · monthly snapshot~Feb 2026 – ~Mar 2026 · 28 days · monthly snapshot~Mar 2026 – present · 6 months · monthly snapshot

Change History

22 versions recorded

  1. Mar 2026 — Present [monthly]

    Terminated PHASE1

    Status: Active Not Recruiting → Terminated

  2. Feb 2026 — Mar 2026 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  3. Sep 2025 — Feb 2026 [monthly]

    Recruiting PHASE1

  4. Mar 2025 — Sep 2025 [monthly]

    Recruiting PHASE1

  5. Dec 2024 — Mar 2025 [monthly]

    Recruiting PHASE1

▶ Show 17 earlier versions

  1. Sep 2024 — Dec 2024 [monthly]

    Recruiting PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE1

  3. Jun 2024 — Jul 2024 [monthly]

    Recruiting PHASE1

  4. Dec 2023 — Jun 2024 [monthly]

    Recruiting PHASE1

  5. Oct 2023 — Dec 2023 [monthly]

    Recruiting PHASE1

  6. Sep 2022 — Oct 2023 [monthly]

    Recruiting PHASE1

  7. May 2021 — Sep 2022 [monthly]

    Recruiting PHASE1

  8. Jan 2021 — May 2021 [monthly]

    Recruiting PHASE1

  9. Sep 2020 — Jan 2021 [monthly]

    Recruiting PHASE1

  10. Jun 2020 — Sep 2020 [monthly]

    Recruiting PHASE1

  11. Apr 2020 — Jun 2020 [monthly]

    Recruiting PHASE1

  12. Jun 2019 — Apr 2020 [monthly]

    Recruiting PHASE1

  13. Dec 2018 — Jun 2019 [monthly]

    Recruiting PHASE1

  14. Oct 2018 — Dec 2018 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  15. Aug 2018 — Oct 2018 [monthly]

    Not Yet Recruiting PHASE1

  16. Jun 2018 — Aug 2018 [monthly]

    Not Yet Recruiting PHASE1

  17. Mar 2018 — Jun 2018 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • M.D. Anderson Cancer Center
  • National Cancer Institute (NCI)
Data source: M.D. Anderson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations